Therapeutic Delivery – Products

The collaborative center will help to lower barriers to RNA innovation and discovery.

N4 Pharma Plc, the company developing Nuvec®, a novel delivery system designed to carry nucleotides to be developed as cancer treatments and vaccines, has entered into a research collaboration agreement with SRI.

Applied Biophysics Forum promises real-world data from nucleic acid drug delivery researchers.

Optimer delivery vehicle has been shipped to a pharma partner for external evaluation. The specific delivery vehicle could generate new precision therapies for liver disease.

In a significant stride towards advancing nanoparticle drug delivery manufacturing technology, German pharmatech company, leon-nanodrugs GmbH (LEON), proudly announces a pioneering technical evaluation by CMAC, University of Strathclyde.

Growth of suppository manufacturing capabilities addresses increasing market demand to meet the needs
of geriatric and pediatric patients, and women’s health.

N4 Pharma PLC (AIM: N4P), recently acquired a controlling interest in Nanogenics Limited.

This article explores how scientists are tackling the challenges and intensifying efforts to develop mRNA therapeutics for different diseases.

Aiming to improve exosome purification process that is currently slowing adoption of promising gene therapies and other new modalities.

Study met primary endpoint and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE® in 30 seconds using Halozyme’s proprietary high-volume auto-injector.